BiogenBIIB
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Employees: 7,570
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.69% less ownership
Funds ownership: 92.53% [Q2] → 90.84% (-1.69%) [Q3]
3% less funds holding
Funds holding: 922 [Q2] → 892 (-30) [Q3]
15% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 117
18% less capital invested
Capital invested by funds: $31.2B [Q2] → $25.5B (-$5.73B) [Q3]
24% less call options, than puts
Call options by funds: $216M | Put options by funds: $284M
27% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 8 (-3) [Q3]
29% less repeat investments, than reductions
Existing positions increased: 261 | Existing positions reduced: 370
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
16 analyst ratings
Wells Fargo Mohit Bansal 31% 1-year accuracy 8 / 26 met price target | 17%upside $165 | Equal-Weight Maintained | 10 Jan 2025 |
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target | 57%upside $220 | Buy Maintained | 8 Jan 2025 |
Piper Sandler Christopher Raymond 10% 1-year accuracy 3 / 30 met price target | 2%downside $138 | Neutral Downgraded | 2 Jan 2025 |
BMO Capital Evan Seigerman 44% 1-year accuracy 7 / 16 met price target | 17%upside $164 | Market Perform Downgraded | 20 Dec 2024 |
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 27%upside $178 | Neutral Reinstated | 10 Dec 2024 |
Financial journalist opinion
Based on 16 articles about BIIB published over the past 30 days
